

JAN 1 3 2004



OFFICE OF PETITIONS

PTO/SB/64 (11-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PEMATION FOR REVIVAL OF AN APPLICATION FOR PATENT ABANDONED UNINTENTIONALLY UNDER 37 CFR 1.137(b)		Docket Number (Optional) <i>R-</i> 477
First named inventor: Keith D. ALLEN		
Application No.: 09/904, 180	Art Unit: 1630	<i>p</i>
Filed: July 11, 2001	Examiner: Suil	Ivan, Daniel M.
Application No.: 09/904, 180  Filed: July 11, 2001  Title: Transgenic Mice Containing Stefin Inhibitor Gene Disruptions  Attention: Office of Petitions	Homolog p	rolease
Attention: Office of Petitions  Mail Stop Petition  Commissioner for Patents  P.O. Box 1450  Alexandria, VA 22313-1450  FAX: (703) 872-9306		
NOTE: If information or assistance is needed in completing th Information at (703) 305-9282.	is form, please cont	act Petitions
The above-identified application became abandoned for failure to file a notice or action by the United States Patent and Trademark Office. The expiration date of the period set for reply in the Office notice or action practually obtained.	date of abandonme	ent is the day after the
APPLICANT HEREBY PETITIONS FOR REVIVAL O	F THIS APPLICATI	ON
NOTE: A grantable petition requires the following items:  (1) Petition fee;  (2) Reply and/or issue fee;  (3) Terminal disclaimer with disclaimer feerequired filed before June 8, 1995; and for all design appli  (4) Statement that the entire delay was unintentional	cations; and	ant applications
1. Petition fee Small entity-fee \$(37 CFR 1.17(m)). Applicant of Not Required)	claims small entity s	tatus. See 37 CFR 1.27.
Other than small entity - fee \$(37 CFR 1.17(m))		
2. Reply and/or fee  A. The reply and/or fee to the above-noted Office action in the form of Amendment Accompanying RCE  has been filed previously on  vis enclosed herewith.  B. The issue fee of \$ has been paid previously on  is enclosed herewith.	·	tify type of reply):

[Page 1 of 2]

This collection of information is required by 37 CFR 1.137. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Petition, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

3. Terminal disclaimer with disclaimer fee	
Since this utility/plant application was filed	on or after June 8, 1995, no terminal disclaimer is required.
	37 CFR 1.20(d)) of \$ for a small entity or \$ for equired period of time is enclosed herewith (see PTO/SB/63).
filing of a grantable petition under 37 CFR 1.13	equired reply from the due date for the required reply until the 37(b) was unintentional. [NOTE. The United States Patent and formation if there is a question as to whether either the der 37 CFR 1.137(b) was unintentional (MPEP
	become public. Credit card information should not card information and authorization on PTO-2038.
January 5, 2003	Kelly Duart Signature
O Date	Signature
Telephone (650) 569-5100	Kelly L. Quast Reg No. 52, 141
Number.	Typed or printed name
	1031 Bing Street Address
	Address
Enclosures: Fee Payment	San Carlos (A 95051
☑ Reply	Address
☐ Terminal Disclaimer Form	
Additional sheets containing sta	tements establishing unintentional delay
☐ Other:	
CERTIFICATE OF MAI	LING OR TRANSMISSION [37 CFR 1.8(a)]
I hereby certify that this correspondence is being	
deposited with the United States Postal S	Service on the date shown below with sufficient postage as to: <b>Mail Stop Petition</b> , Commissioner for Patents,
transmitted by facsimile on the date show (703) 872-9306.	wn below to the United States Patent and Trademark Office at
01-05-04	Don Ma
Date	Signature
	Signature DUN MIXON
	Type or printed name of person signing certificate

N 0 9 2004 2			
3	CERTIFICATE	OF MAILING	
Assistant Commissioner for	espondence is being deposited with the United St Patents, Washington, D.C. 20231.	ates Postal Service as first class n	mail in an envelope addressed to:
Typed or Printed Name	Don Mixon		JAN 1 3 2004
Signature	1 Jm Miss	Date	January 5, 2004
			OFFICE OF PETITION

	Application Number	09/904,180
RENEWED PETITION TO REVIVE UNDER 37 C.F.R. §1.137(b)	Confirmation Number	1187
	Filing Date	July 11, 2001
	First Named Inventor	Keith D. Allen
Address to:	Examiner	Daniel M. Sullivan
Commissioner for Patents	Group Art	1636
P.O. Box 1450 Alexandria, VA 22313-1450	Title	Transgenic Mice Containing Stefin Homolog Protease Inhibitor Gene Disruptions
	Attorney Docket No.	R-477

Sir:

The above referenced application has unintentionally fallen abandoned due to the inadvertent failure to timely file a proper reply to the final Office Action mailed January 14, 2003. A reply was filed April 14, 2003, which was not considered by the Examiner to place the application in condition for allowance, and therefore was not entered (see Advisory Action mailed May 7, 2003). Applicant unintentionally failed to file an amendment responsive to the Advisory Action within the six month statutory period ending July 14, 2003. Applicant initially petitioned to revive the application on October 17, 2003, which petition included an amendment believed to place the claims in condition for allowance. However, it was determined by the Examiner that the response filed October 17, 2003 did not place the claims in condition for allowance. Therefore the amendment was not entered, and the petition to revive was dismissed. As a result, Applicant is hereby filing a Renewed Petition to Revive the application.

Attached herewith is a renewed Petition for Revival of an Unintentionally Abandoned Application under 37 C.F.R. § 1.137(b). Applicant hereby states that the entire delay in properly responding to the outstanding Office Action(s) was unintentional. Applicant further submits herewith a Request for Continued Examination, and an Amendment in response to the Office Action dated January 14, 2003, attached herewith.

Application No. 09/904,180 Deltagen Docket No. R-477

Applicant requests entry and consideration of the amendments and remarks set forth in the enclosed Amendment and reinstatement of the application to active status. In view of the amendments to the claims and the remarks set forth below, reconsideration and allowance are respectfully requested.

It is believed that all required submissions are included herewith in order to renew the Petition to Revive and revive the instant application under 37 C.F.R. § 1.137(b), which action is respectfully requested.

The Commissioner is hereby authorized to charge any underpayment of fees associated with this communication, including any necessary fees for extensions of time, or credit any overpayment to Deposit Account No. 50-1271 under order No. R-477.

> Respectfully submitted, DELTAGEN, INC.

Date: January 5, 2003

By: Kelly Duard
Kelly L. Quast Reg. No. 52,141

DELTAGEN, INC. 1031 Bing Street

San Carlos, CA 94070

Telephone: (650) 569-5100 Facsimile: (650) 569-5280

	NC NAITT							omplete if Known		
EMARGE TRA		AL	• 🛂	Applic	ation I	Numbe	er	09/904,180	$\mathbb{R}$	<b>ECEIV</b>
for E	Y 2004		L	Filing	Date			July 11, 2001		N 1 3 2
Effective 10/01/2003. Patent fe		oviolo o		First N	Named	Inven	tor	Keith D. Allen	JP	4M I 2 4
	<u> </u>		$-\Gamma$	Exam	iner N	ame		Daniel M. Sullivan	OFFIC	CE OF PET
Applicant claims small entity	status. See 37 CFR 1.	27	_ [7	Art Ur	nit			1636		~~~
TOTAL AMOUNT OF PAYMEN	NT (\$) 385.00			Attorn	ey Do	cket N	0.	R-477	, .	
METHOD OF PAYMENT	(check all that apply)				-	FEE	CA	LCULATION (continued)		
Check Credit card	Money Other	None 3	. AD	DITIO	ONAL	. FEE	s			
Deposit Account:	Order L	L <u>a</u>	arge E	ntity	Small	Entity				
Deposit Fo 1071				Fee (\$)	Fee Code	Fee (\$)		Fee Description		Fee Paid
Account Sumber 50-1271		1		130	2051		Surch	harge - late filing fee or oath		
Deposit Account Deltagen, Inc.		]   1	1052	50	2052			harge - late provisional filing fee o	or	
Name	!! 45 - 4 1. 1	J  ₁	1053	130	1053			English specification		
The Director is authorized to: (check Charge fee(s) indicated below	Credit any overpaym	ents 1	1812 2	2,520	1812	2,520	For fil	ling a request for ex parte reexar	mination	
Charge any additional fee(s) or any			1804	920*	1804	920*		uesting publication of SIR prior to niner action	,	
Charge fee(s) indicated below, exc		1 1	1805 1	1.840*	1805	1.840*		uesting publication of SIR after		
o the above-identified deposit accoun	l.					•	Exam	miner action		<del></del>
FEE CALCU	LATION		1251	110	2251			ension for reply within first month	unth.	
I. BASIC FILING FEE			1252	420	2252	210		ension for reply within second mo		
arge Entity Small Entity Fee Fee Fee Fee Fee De:	scription Fee F		1253 1254 1	950	2253 2254			ension for reply within third month ension for reply within fourth mon		
Code (\$)   Code (\$)			1255 2		2255			ension for reply within fourth month		
1	filing fee	11	1255 2 1401	330		.,		• •		
	n filing fee	4 1	1401	330	2401 2402			ce of Appeal g a brief in support of an appeal		
	filing fee		1402	290	2402		•	g a brief in support of an appear uest for oral hearing		
	ue filing fee sional filing fee	<b></b>	1403 1451 1				•	tion to institute a public use proce	edino	
			1452	110	2452			tion to revive - unavoidable	,comig	
SUBTO	TAL (1) (\$)		1453 1		2453			tion to revive - unintentional		
2. EXTRA CLAIM FEES FOR		CHE	1453 1 1501 1		2501			tion to revive - unintentional ty issue fee (or reissue)		
Extra C	Fee from Claims below Fee		1502	480	2502		•	ign issue fee		
Total Claims	▃▎ <del>▘</del> ┡──┤╬	┩	1503	640	2503	320	Plan	nt issue fee		
Claims - 3** =	× <u></u> _ = <u></u>	┈┈╽	1460	130	1460	130	Petit	tions to the Commissioner		

Total Claims Independent	-20**	-   X   -   -	1503	640	2503	320 Plant issue fee	
Claims	- 3**	=	1460	130	1460	130 Petitions to the Commissioner	
Multiple Depe	naent	L =j	1807	50	1807	50 Processing fee under 37 CFR 1.17(q)	
Large Entity Fee Fee	Small Entity Fee Fee	For Depositation	1806	180	1806	180 Submission of Information Disclosure Stmt	
Code (\$)	Code (\$)	Fee Description	8021	40	8021	Recording each patent assignment per property (times number of properties)	
1202 18 1201 86	2202 9 2201 43	Claims in excess of 20 Independent claims in excess of 3	1809	770	2809	385 Filing a submission after final rejection (37 CFR 1.129(a))	
1203 290	2203 145	Multiple dependent claim, if not paid	1810	770	2810	385 For each additional invention to be	
1204 86	2204 43	** Reissue independent claims over original patent	1801	770	2801	examined (37 CFR 1.129(b)) 385 Request for Continued Examination (RCE)	385.00
1205 18	2205 9	** Reissue claims in excess of 20 and over original patent	1802	900	1802	900 Request for expedited examination of a design application	
	SUBT	TOTAL (2) (\$)	Other				
· · · · · · · · · · · · · · · · · · ·			*Reduced by Basic Filing Fee Paid CURTOTAL (2) (c) 205 00				

(Complete (if applicable)) SUBMITTED BY Registration No. Name (Print/Type) Telephone 650-569-5100 Kelly L. Quast 52,141 (Attorney/Agent) Men Kelly 01/05/04 Signature Date

\*Reduced by Basic Filing Fee Paid


SUBTOTAL (3)

(\$) 385.00

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

\*\*or number previously paid, if greater; For Reissues, see above



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/904,180	07/11/2001	Keith D. Allen	R-477	1187
75	590 10/16/2003		EXAM	INER
DELTAGEN,			SULLIVAN,	DANIEL M
1003 Hamilton Menlo Park, C			ART UNIT	PAPER NUMBER
•			1636	18
			DATE MAILED: 10/16/2001	2

Please find below and/or attached an Office communication concerning this application or proceeding.

NOV - 4 2003

	JAN D 9	JC9.	•
	RADE		ndonmen

Application No.	Applicant(s)	
09/904,180	ALLEN, KEITH D.	
Examiner	Art Unit	
Daniel M Sullivan	1636	

Dainor III Camiran
The MAILING DATE of this communication appears on the cover sheet with the correspondence address
This application is abandoned in view of:
<ul> <li>Applicant's failure to timely file a proper reply to the Office letter mailed on <u>07 May 2003</u>.</li> <li>(a) ☐ A reply was received on (with a Certificate of Mailing or Transmission dated ), which is after the expiration of the period for reply (including a total extension of time of month(s)) which expired on</li> <li>(b) ☐ A proposed reply was received on, but it does not constitute a proper reply under 37 CFR 1.113 (a) to the final rejection.</li> </ul>
(A proper reply under 37 CFR 1.113 to a final rejection consists only of: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114).
(c) A reply was received on but it does not constitute a proper reply, or a bona fide attempt at a proper reply, to the non-final rejection. See 37 CFR 1.85(a) and 1.111. (See explanation in box 7 below).
(d) No reply has been received.
2. Applicant's failure to timely pay the required issue fee and publication fee, if applicable, within the statutory period of three months from the mailing date of the Notice of Allowance (PTOL-85).  (a) The issue fee and publication fee, if applicable, was received on (with a Certificate of Mailing or Transmission dated
), which is after the expiration of the statutory period for payment of the issue fee (and publication fee) set in the Notice of Allowance (PTOL-85).
(b) ☐ The submitted fee of \$ is insufficient. A balance of \$ is due.
The issue fee required by 37 CFR 1.18 is \$ The publication fee, if required by 37 CFR 1.18(d), is \$
(c) The issue fee and publication fee, if applicable, has not been received.
Applicant's failure to timely file corrected drawings as required by, and within the three-month period set in, the Notice of Allowability (PTO-37).
(a) Proposed corrected drawings were received on (with a Certificate of Mailing or Transmission dated), which is after the expiration of the period for reply.
(b) No corrected drawings have been received.
The letter of express abandonment which is signed by the attorney or agent of record, the assignee of the entire interest, or all of the applicants.
The letter of express abandonment which is signed by an attorney or agent (acting in a representative capacity under 37 CFR 1.34(a)) upon the filing of a continuing application.
The decision by the Board of Patent Appeals and Interference rendered on and because the period for seeking court review of the decision has expired and there are no allowed claims.
7. 🔀 The reason(s) below:
Abandonment of the Application was confirmed by Kelly Quast on 14 September 2003.  DAVID GUZO  PRIMARY EXAMINER

Petitions to revive under 37 CFR 1.137(a) or (b), or requests to withdraw the holding of abandonment under 37 CFR 1.181, should be promptly filed to minimize any negative effects on patent term.

U.S. Patent and Trademark Office
PTOL-1432 (Rev. 04-01)

Notice of Abandonment

Part of Paper No. 18

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

Paper No. 22

DELTAGEN, INC. 2010 1003 HAMILTON AVENUE MENLO PARK, CA 94025

COPY MAILED

NOV 2 6 2003

OFFICE OF PETITIONS

In re Application of Allen, Keith D. Application No. 09/904,180 Filed: July 11, 2001 Attorney Docket No. R-477

ON PETITION

This is a decision on the petition under 37 CFR 1.137(b), filed October 24, 2003, to revive the above-identified application.

The petition is **DISMISSED**.

Any request for reconsideration must be submitted within TWO (2) MONTHS from the mail date of this decision. No further petition fee is required for the request. Extensions of time under 37 CFR 1.136(a) are permitted. The reconsideration request should include a cover letter entitled "Renewed Petition under 37 CFR 1.137(b)." This is **not** a final agency action within the meaning of 5 U.S.C. § 704.

This application became abandoned for failure to timely reply to the final Office action mailed January 14, 2003. No extensions of time under the provisions of 37 CFR 1.136(a) were obtained. Accordingly, this application became abandoned on April 15, 2003. A Notice of Abandonment was mailed October 16, 2003.

A grantable petition under 37 CFR 1.137(b) must be accompanied by:

(1) the required reply,

(2) the petition fee,

(3) a statement that the entire delay in filing the required reply from the due date for the reply until the filing of a grantable petition pursuant to 37 CFR 1.137(b) was unintentional, and

(4) a terminal disclaimer and fee if the application was filed on or before June 8, 1995 or if the application is a design application.

Where there is a question as to whether either the abandonment or the delay in filing a petition under 37 CFR 1.137 was unintentional, the Commissioner may require additional information.<sup>2</sup>

The instant petition lacks item (1). The amendment submitted with the instant petition on October 24, 2003, failed to place the application in condition for allowance. A proper reply to a final rejection under 37 CFR 1.113 may be: (1) an amendment which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee); or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. Petitioner must submit one of the above documents in order to revive the above-identified application. An advisory action from the examiner is enclosed.

In a nonprovisional application abandoned for failure to prosecute, the required reply may be met by the filing of a continuing application. In an application or patent, abandoned or lapsed for failure to pay the issue fee or any portion thereof, the required reply must be the payment of the issue fee or any outstanding balance thereof.

<sup>&</sup>lt;sup>2</sup> See MPEP 711.03(c)(III)(C) and (D).

The file does not indicate a change of address has been submitted, although the address given on the petition differs from the address of record. If appropriate, a request to change the address of record should be filed. A courtesy copy of this decision is being mailed to the address given on the petition; however, the Office will mail all future correspondence solely to the address of record.

Further correspondence with respect to this matter should be addressed as follows:

By mail:

Mail Stop PETITION Commissioner for Patents Post Office Box 1450 Alexandria, VA 22313-1450

By facsimile:

(703) 308-6916

Attn: Office of Petitions

By hand:

Office of Petitions 2201 South Clark Place Crystal Plaza 4, Suite 3C23 Arlington, VA 22202

Effective December 1, 2003, the Office of Petitions can no longer receive hand-carried correspondence, or facsimile transmissions of correspondence. The centralized location for hand-carried correspondence is the existing Customer Window located at:

2011 South Clark Place Crystal Plaza 1 Lobby

Room 1B03

Arlington, VA 22202

The centralized facsimile number is (703) 872-9306.

Telephone inquiries should be directed to Paralegal Liana Chase at (703) 306-0482.

Karen Creasy

Petitions Examiner Office of Petitions


Office of the Deputy Commissioner for Patent Examination Policy

Enclosure:

Advisory Action

CC:

Kelly L. Quast DELTAGEN, INC. 1031 Bing Street San Carlos, CA 94070



Application No.	Applicant(s)		
09/904,180	ALLEN, KEITH D.		
Examiner	Art Unit		
Daniel M Sullivan	1636		

--The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

THE REPLY FILED 24 October 2003 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.

Examination (RCE) in compliance with 37 CFR 1.114.
PERIOD FOR REPLY [check either a) or b)]
a) The period for reply expiresmonths from the mailing date of the final rejection.
b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.  ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).
Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).
1. A Notice of Appeal was filed on Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.
2. The proposed amendment(s) will not be entered because:
(a) ☑ they raise new issues that would require further consideration and/or search (see NOTE below);
(b) they raise the issue of new matter (see Note below);
(c) they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or
(d) 🔲 they present additional claims without canceling a corresponding number of finally rejected claims.
NOTE: <u>See Continuation Sheet</u> .
3. Applicant's reply has overcome the following rejection(s):
4. Newly proposed or amended claim(s) 1,2 and 4 would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).
5. ☑ The a) ☐ affidavit, b) ☐ exhibit, or c) ☑ request for reconsideration has been considered but does NOT place the application in condition for allowance because: <u>See Continuation Sheet</u> .
6. The affidavit or exhibit will NOT be considered because it is not directed SOLELY to issues which were newly raised by the Examiner in the final rejection.
7. ☑ For purposes of Appeal, the proposed amendment(s) a) ☑ will not be entered or b) ☐ will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.
The status of the claim(s) is (or will be) as follows:
Claim(s) allowed:
Claim(s) objected to:
Claim(s) rejected:
Claim(s) withdrawn from consideration:
8. The drawing correction filed on is a) approved or b) disapproved by the Examiner.
9. Note the attached Information Disclosure Statement(s)( PTO-1449) Paper No(s)
10. Other:
Anne-marie Jalk
PRIMARY FYARIDIED



Continuation of 2. NOTE: In the proposed amendment to claim 3, the word "construct" is mistakenly deleted from the first line such that the claim is directed to "a method of producing a targeting", which raises a new ground for objection, or rejection of the claim under 35 U.S.C. §112, second paragraph.

Continuation of 5. does NOT place the application in condition for allowance because: The proposed amendments to not fully address the rejection under 35 U.S.C. §112, first paragraph, of claims 5, 8, 9, 10, 11 and 20-25 as lacking enablement for the full scope of the claimed subject matter. In the remarks that accompany the amendments, Applicant asserts that because the mice and cells of the claims are limited to comprising a homozygous disruption of the stefin homolog gene comprising SEQ ID NO: 1 and exhibiting increased activity or a neurophsychological disorder, the claims are fully enabled by the specification (page 7, fourth full paragraph). However, the previous Office Actions clearly indicate that the specification is enabling only for "a homozygous KNOCKOUT mouse comprising a disruption in the stefin homolog gene comprising the sequences set forth as SEQ ID NO: 1 and exhibiting phenotypic features such as HYPERACTIVITY, DECREASED PROPENSITY TO DESPAIR, SCHIZOPHRENIC BEHAVIOUR AND DECREASED PREPULSE INHIBITION as compared to wild type mice" (Office Action mailed 19 June 2002, paragraph bridging pages 3-4, emphasis added; see also the Office Action mailed 14 January 2003, page 3). In other words, the disruption of the stefin homolog gene must result in loss of expression. In contrast, the proposed claims 5, 8, 9, 10, 11 and 20-25 still encompass a transgenic mouse and cells comprising any disruption (i.e., insertion, deletion or substitution in any portion of the gene; 19 June Office Action, page 5, first full paragraph) and a transgenic mouse that exhibits any neuropsychological disorder. Thus, had the proposed amendments been entered, the scope of claims 5, 8, 9, 10, 11 and 20-25 would still encompass subject matter indicated in previous Office Actions to lack enablement.